Larimar Therapeutics, Inc. financial data

Symbol
LRMR on Nasdaq
Industry
Pharmaceutical Preparations
Location
Three Bala Plaza East. Suite 506, Bala Cynwyd, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
ZAFGEN, INC. (to 5/19/2020), ZAFGEN INC (to 11/3/2008)
Latest financial report
10-Q - Q3 2024 - Oct 30, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.28K % -5.1%
Debt-to-equity 10.8 % -13.6%
Return On Equity -35.9 % -10.1%
Return On Assets -32.4 % -11.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.8M shares +45.3%
Common Stock, Shares, Outstanding 63.8M shares +45.3%
Entity Public Float 20.6M USD -78.2%
Common Stock, Value, Issued 64K USD +48.8%
Weighted Average Number of Shares Outstanding, Basic 63.8M shares +45.3%
Weighted Average Number of Shares Outstanding, Diluted 63.8M shares +45.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 57.2M USD +136%
General and Administrative Expense 16.6M USD +20.1%
Operating Income (Loss) -73.8M USD -93.9%
Nonoperating Income (Expense) 8.99M USD +93.1%
Net Income (Loss) Attributable to Parent -64.8M USD -94%
Earnings Per Share, Basic -1.14 USD/shares -93.2%
Earnings Per Share, Diluted -1.14 USD/shares -93.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.1M USD -9.44%
Cash, Cash Equivalents, and Short-term Investments 204M USD +113%
Assets, Current 213M USD +117%
Property, Plant and Equipment, Net 779K USD +29.6%
Operating Lease, Right-of-Use Asset 3.03M USD +4.42%
Other Assets, Noncurrent 621K USD -2.05%
Assets 219M USD +111%
Accounts Payable, Current 1.69M USD +123%
Employee-related Liabilities, Current 2.38M USD +44%
Accrued Liabilities, Current 13.6M USD +166%
Liabilities, Current 16.3M USD +148%
Operating Lease, Liability, Noncurrent 4.34M USD -7.39%
Liabilities 20.6M USD +83.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 358K USD +5014%
Retained Earnings (Accumulated Deficit) -240M USD -36.9%
Stockholders' Equity Attributable to Parent 198M USD +114%
Liabilities and Equity 219M USD +111%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD -37.9%
Net Cash Provided by (Used in) Financing Activities 162M USD
Net Cash Provided by (Used in) Investing Activities -68.4M USD -174%
Common Stock, Shares Authorized 115M shares 0%
Common Stock, Shares, Issued 63.8M shares +45.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 83.4M USD -1.56%
Deferred Tax Assets, Valuation Allowance 142M USD +8.36%
Deferred Tax Assets, Gross 143M USD +8.29%
Operating Lease, Liability 5.36M USD -0.52%
Depreciation 80K USD +2.56%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.4M USD -93.3%
Lessee, Operating Lease, Liability, to be Paid 6.81M USD -6.12%
Property, Plant and Equipment, Gross 2.25M USD +28.7%
Operating Lease, Liability, Current 1.03M USD +44.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.47M USD +16.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.54M USD +23.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.45M USD -22.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.27M USD +3.51%
Deferred Tax Assets, Operating Loss Carryforwards 45.2M USD +7.09%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.19M USD +6.35%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 8.31M USD +13.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%